SENN AB Stock Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Sales 2024 * | 67.55M 6.19M 0 | Sales 2025 * | 91.65M 8.4M 0 | Capitalization | 150M 13.74M 0 |
---|---|---|---|---|---|
Net income 2024 * | -15M -1.37M - | Net income 2025 * | -4M -366K - | EV / Sales 2024 * | 2.1 x |
Net cash position 2024 * | 8M 733K 0 | Net cash position 2025 * | 9M 824K 0 | EV / Sales 2025 * | 1.54 x |
P/E ratio 2024 * |
-10
x | P/E ratio 2025 * |
-36.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.56% |
Latest transcript on SENN AB
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 17-12-31 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 16-10-31 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 10-08-17 | |
Director/Board Member | 59 | 14-10-14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
-17.60% | 11.52B | |
+39.11% | 3.27B | |
-20.67% | 2.02B | |
-29.30% | 1.44B | |
+11.45% | 1.01B | |
-6.33% | 719M | |
-30.75% | 418M | |
-51.02% | 339M | |
-2.58% | 284M |